Accepted for/Published in: JMIR Research Protocols
Date Submitted: May 9, 2023
Date Accepted: Oct 10, 2023
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
“A Machine Learning Model to Predict Patients' Adherence Behavior and Decision Support System in Metastatic Breast Cancer Patients: Protocol for a Randomized Controlled Study”
ABSTRACT
Background:
Adherence to oral anticancer treatment is a critical issue in the disease trajectory of breast cancer patients. Given the impact of non-adherence on clinical outcomes and the associated economic burden for the healthcare system, finding effective ways to increase treatment adherence is particularly relevant.
Objective:
The primary endpoint is to evaluate the effectiveness of a decision support system (DSS) in promoting adherence to oral anticancer treatments in a sample of metastatic breast cancer patients. The secondary endpoint is to collect a set of new physical, psychosocial, behavioral, and quality-of-life variables that might be used to refine the preliminary version of a machine-learning model to predict patients' adherence behavior.
Methods:
The current prospective observational, randomized controlled study is nested in a large-scale international project named “Enhancing therapy adherence among metastatic breast cancer patients" (Pfizer - Tracking Number 65080791), aimed to develop a predictive model of non-adherence and associated DSS, and guidelines to foster patients' engagement and therapy adherence among metastatic breast cancer patients. A hundred patients consecutively admitted at the European Institute of Oncology at the Division of Medical Senology will be enrolled. 50 metastatic breast cancer patients will be exposed to the DSS for three months (experimental group) and 50 patients will be not exposed to the intervention (control group). Furthermore, each participant will fill out a weekly medication diary and a set of standardized self-reports at established time points. The study was approved by the European Institute of Oncology (IEO) Ethical Committee (n. R1786/22-IEO 1907).
Results:
The recruitment process will start in May 2023.
Conclusions:
The contribution of the machine learning techniques through introducing the risk-predictive models integrated into the DSS will permit to support medication adherence in cancer patients. Clinical Trial: NA
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.